Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01148498
Previous Study | Return to List | Next Study

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01148498
First received: June 18, 2010
Last updated: September 18, 2012
Last verified: August 2012

June 18, 2010
September 18, 2012
August 2010
August 2012   (final data collection date for primary outcome measure)
Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3) [ Time Frame: Baseline up to 112 days post drug administration ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01148498 on ClinicalTrials.gov Archive Site
  • Mean change in plasma levels of Aβ1-42 after solanezumab infusion [ Time Frame: Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose ] [ Designated as safety issue: No ]
  • Mean change in plasma levels of Aβ1-40 species after solanezumab infusion [ Time Frame: Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose ] [ Designated as safety issue: No ]
  • Mean change in plasma levels of modified Aβ species after solanezumab infusion [ Time Frame: Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type

The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Alzheimer's Disease
Drug: solanezumab
400mg administered once intravenously
Other Names:
  • LY2062430
  • A Beta Antibody
  • Experimental: Group 1
    Older adults with mild Dementia Alzheimer's Type (DAT)
    Intervention: Drug: solanezumab
  • Experimental: Group 2
    Older adult controls with possible Alzheimer's Disease Pathology
    Intervention: Drug: solanezumab
  • Experimental: Group 3
    Older adult controls with no evidence of Alzheimer's Disease
    Intervention: Drug: solanezumab
  • Experimental: Group 4
    Younger subjects who are assumed to have no cognitive impairment
    Intervention: Drug: solanezumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Individuals in Groups 1, 2, and 3, described below, will be participants in the longitudinal studies of memory and aging at the Washington University Alzheimer's Disease Research Center (WU-ADRC). These participants must have results from apolipoprotein E (ApoE) genotyping from the WU-ADRC. At the beginning of the study they must be between 45 and 90 years of age and if a female of childbearing potential, not be breastfeeding, test negative for pregnancy, and be using a medically accepted form of birth control at the time of the infusion and for 6 months afterward. Subjects must also meet the criteria below for each study group

Group 1, Mild dementia of Alzheimer's type (DAT):

  • Have mild DAT, as determined by Clinical Dementia Rating (CDR) of 0.5 or 1
  • Have florbetapir PET imaging findings consistent with underlying AD pathology.

Group 2, Older Adult Controls with Possible AD Pathology:

Have no cognitive impairment as indicated by a CDR rating of 0. Have possible AD pathology, as determined by florbetapir PET imaging.

Group 3, Older Adult Controls with No Evidence of AD Pathology:

Have no cognitive impairment as indicated by a CDR rating of 0. Have no evidence of AD pathology as determined by florbetapir PET imaging.

Individuals recruited into Group 4 will not be participants in the longitudinal studies of memory and aging at WU-ADRC. To be included in Group 4, individuals must meet these criteria:

  • Are at least 18 years and <35 years of age at the beginning of the study and if a female of childbearing potential, is not breastfeeding, tests negative for pregnancy and is using highly effective contraception at the time of the solanezumab infusion and for 6 months following infusion
  • Have a Folstein Mini-Mental State Examination (MMSE) score of 29 to 30 at the beginning of the study

Exclusion Criteria:

  • Have previously completed or withdrawn from this study or any other study investigating solanezumab
  • Does not have good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
  • Has allergies to humanized monoclonal antibodies
  • Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
  • Has a history of chronic alcohol or drug abuse/dependence
  • Is clinically judged by the investigator to be at serious risk for suicide
  • Has a recent (within 6 months before screening) or current laboratory result (if available) indicating a clinically significant laboratory abnormality
  • Has Electrocardiogram (ECG) abnormalities obtained at screening that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study. Bazett's corrected QT [QTcB] interval must be evaluated and must not exceed >458 msec in males or >474 msec in females
  • At screening, has alanine transaminase (ALT/SGPT) values greater than or equal to 2 times the upper limit of normal (ULN) of the performing laboratory, aspartate transaminase (AST/SGOT) values greater than or equal to 3 times the ULN, or total bilirubin values greater than or equal to 2 times the ULN
  • Has had IgG therapy (sometimes called gamma globulin therapy) within the last year or previous participation in any other study investigating active immunization against Aβ
  • Requires treatment with other monoclonal antibodies
Both
18 Years to 90 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01148498
13572, H8A-MC-LZAT
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP